Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Blood (2018) 132 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2018-99-119974

Published: 2018

Journal Articles

Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Edward D. Ball, MD, Bruno C. Medeiros, MD, Larissa Balaian, PhD, Tracy Roque, Sue Corringham, Richa Rajwanshi, Steven Coutre, Jason R Gotlib, MD, MS, Asad Bashey, MD, PhD, Karen Messer

Blood (2010) 116 (21): 3286.

https://doi.org/10.1182/blood.V116.21.3286.3286

Published: 2010

Journal Articles

Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development

Alessandra Cesano, MD, Jason R Gotlib, MD, MS, Norman J. Lacayo, MD, Santosh Putta, Ph.D., Alan Lackey, MS, Urte Gayko, Ph.D., Steven M. Kornblau, MD

Blood (2010) 116 (21): 4843.

https://doi.org/10.1182/blood.V116.21.4843.4843

Published: 2010

Journal Articles

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

Animesh Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Richard M Stone, M.D., Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 459.

https://doi.org/10.1182/blood.V116.21.459.459

Published: 2010

Journal Articles

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes

Daniel A Pollyea, MD, Aparna Raval, PhD, Brenda Kusler, Jason R Gotlib, MD, MS, Ash A. Alizadeh, MD, PhD, Beverly S. Mitchell, MD

Blood (2010) 116 (21): 1889.

https://doi.org/10.1182/blood.V116.21.1889.1889

Published: 2010

Journal Articles

AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.

Mahesh Seetharam, MD, Olga K Weinberg, MD, Li Ren, MS, Lisa Ma, MS, Katie Seo, MS, James L. Zehnder, MD, Jason R Gotlib, MD, MS, Daniel A. Arber, MD

Blood (2009) 114 (22): 2638.

https://doi.org/10.1182/blood.V114.22.2638.2638

Published: 2009

Journal Articles

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill H Chang, MD, PhD, Vincent T Bicocca, Stephen T Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. DenBoer, MSc, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Jason R Gotlib, MD, MS, Michael Deininger, MD, PhD, Brian J. Druker, MD

Blood (2009) 114 (22): 3978.

https://doi.org/10.1182/blood.V114.22.3978.3978

Published: 2009

Journal Articles

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

Animesh D. Pardanani, MBBS, PhD, Jason R Gotlib, MD, MS, Catriona Jamieson, MD, PhD, Jorge Cortes, MD, Moshe Talpaz, MD, Richard Stone, MD, Michael H Silverman, MD, FACP, Jolene Shorr, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 755.

https://doi.org/10.1182/blood.V114.22.755.755

Published: 2009

Journal Articles

A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.

D Ball Edward, MD, Bruno C. Medeiros, MD, Larissa Balaian, PhD, Tracy Roque, Sue Corringham, RN, Richa Rajwanshi, Steve Coutre, MD, Jason R Gotlib, MD, MS, Asad Bashey, MD, PhD, Karen Messer, PhD

Blood (2009) 114 (22): 2049.

https://doi.org/10.1182/blood.V114.22.2049.2049

Published: 2009

Journal Articles

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, MS, Annelie Abrahamsson, MS, Charlene Barroga, PhD, Edward Kavelerchik, MD, Jason R. Gotlib, MD MS, John D. Hood, PhD, Jeffrey Durocher, PhD, Chi Ching Mak, PhD, Glen Noronha, PhD, Richard Soll, PhD, Ayalew Tefferi, MD, Kenneth Kaushansky, MD, Catriona H.M. Jamieson, MD PhD

Blood (2007) 110 (11): 1526.

https://doi.org/10.1182/blood.V110.11.1526.1526

Published: 2007

NARROW

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies

Sample Cryopreservation Does Not Affect Functional Read Outs In SCNP Assays: Implications for Biomarker Development

Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2 V617F Allele Burden

A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes

AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2 V617F Allele Burden.

A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only